BioCryst Pharmaceuticals to Announce Financial Results
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is set to report its financial results for the third quarter of 2024. The anticipated announcement is scheduled for November 4, marking an important date for the company and its stakeholders alike.
Conference Call Scheduled
On the same day as the results release, BioCryst management will conduct a conference call and webcast at 8:30 a.m. ET. This session is designed to discuss the financial outcomes and offer a comprehensive update on the company's corporate developments.
How to Access the Conference Call
Investors and interested parties can join the live call by dialing either 1-844-481-2942 for callers within the United States or 1-412-317-1866 for international participants. Additionally, a live webcast alongside a replay will be accessible in the investor section of BioCryst's official website.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, a dedicated biotechnology firm, focuses on enhancing the well-being of individuals facing complement-mediated and other rare diseases. With a strong foundation in structure-guided drug design, the company aims to develop innovative oral small-molecule and protein therapeutics targeting challenging diseases.
Key Product Offerings
One of BioCryst's notable products is ORLADEYO (berotralstat), recognized as the first oral, once-daily plasma kallikrein inhibitor. The company is actively working on a pipeline consisting of both small-molecule and protein therapies that address various medical needs.
Looking Ahead
As BioCryst Pharmaceuticals moves closer to releasing their financial results, stakeholders are keen to learn about the company’s progress, ongoing research initiatives, and their strategic plans for growth. The upcoming conference call is expected to provide valuable insights into their financial health and operational strategies.
Connecting with BioCryst
For updates and detailed information, interested individuals are encouraged to explore BioCryst’s website or follow the company on LinkedIn. Maintaining an active communication line with investors and healthcare professionals is a priority for BioCryst as it seeks to forge ahead in the biotechnology sector.
Frequently Asked Questions
When will BioCryst report its third quarter financial results?
BioCryst Pharmaceuticals will release its third quarter 2024 financial results on November 4.
What time is the conference call scheduled for?
The conference call is set for 8:30 a.m. ET on the same day as the financial results announcement.
How can I access the conference call?
To access the call, dial 1-844-481-2942 for domestic callers or 1-412-317-1866 for international callers. A webcast will also be available.
What is ORLADEYO?
ORLADEYO (berotralstat) is BioCryst’s first oral plasma kallikrein inhibitor available for once-daily administration.
How can I get in touch with BioCryst?
For inquiries, you can contact John Bluth at +1 919 859 7910 or via email.